To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozogamicin.
Experienced refractory or relapsed disease, treated with standard chemotherapy, without immunotherapy treatment.
Previously undergone standard of care immunotherapy with FDA approved therapies, such as Kymriah™ (CTL019, tisagenlecleucel), blinatumomab or
Age: Greater than or equal to 0 year of age and less than or equal to 26 years of age.
Disease Status - B cell precursor acute lymphoblastic leukemia (ALL) or B cell lymphoma
None
Stanford University
Lead sponsor
The Pediatric Oncology Experimental Therapeutics Investigators' Consortium
Collaborator